Difference between revisions of "SL327"

From MagnetoWiki
Jump to navigation Jump to search
(Created page with 'SL327 is a MAP Kinase Kinase 1/2 (MEK1/2) inhibitor. [http://www.sigmaaldrich.com/catalog/ProductDetail.do?D7=0&N5=SEARCH_CONCAT_PNO%7CBRAND_KEY&N4=S4069%7CSIGMA&N25=0&QS=ON&F=…')
 
(Update perm redirect.)
 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
SL327 is a MAP Kinase Kinase 1/2 (MEK1/2)  inhibitor.
 
SL327 is a MAP Kinase Kinase 1/2 (MEK1/2)  inhibitor.
  
[http://www.sigmaaldrich.com/catalog/ProductDetail.do?D7=0&N5=SEARCH_CONCAT_PNO%7CBRAND_KEY&N4=S4069%7CSIGMA&N25=0&QS=ON&F=SPEC Sigma-Aldrich S4069-5MG] $101
+
[https://www.sigmaaldrich.com/US/en/product/sigma/s4069 Sigma-Aldrich S4069-5MG] $101
  
 
Synonym: α-[Amino-(4-aminophenylthio)methylene)-2-(trifluoromethyl)phenylacetonitrile
 
Synonym: α-[Amino-(4-aminophenylthio)methylene)-2-(trifluoromethyl)phenylacetonitrile
Line 12: Line 12:
  
 
MDL number: MFCD06411432
 
MDL number: MFCD06411432
 +
 +
==Central Administration==
 +
 +
From Kwon and Houpt, 2011:
 +
 +
Dissolve SL327 in 50% DMSO, 50% 0.15M NaCl at 2 ug/ul concentration..  Administer using Hamilton syringe pump over 1 minute: 1 ug/0.5 ul / hemisphere into the CeA immeadiately after 10min access to 0.125% saccharin and 15 min before LiCl injection (12 ml/kg, 0.15 M, i.p.) Inject 0.5 ul over 1 minute; leave injector in place for 1 min after injection to prevent backflow along the injection tract.
 +
 +
[[Category:Taste Aversion]]
 +
[[Category:CTA Experiments]]

Latest revision as of 11:14, 7 December 2021

SL327 is a MAP Kinase Kinase 1/2 (MEK1/2) inhibitor.

Sigma-Aldrich S4069-5MG $101

Synonym: α-[Amino-(4-aminophenylthio)methylene)-2-(trifluoromethyl)phenylacetonitrile

CAS Number: 305350-87-2

Empirical Formula (Hill Notation): C16H12F3N3S

Molecular Weight: 335.35

MDL number: MFCD06411432

Central Administration

From Kwon and Houpt, 2011:

Dissolve SL327 in 50% DMSO, 50% 0.15M NaCl at 2 ug/ul concentration.. Administer using Hamilton syringe pump over 1 minute: 1 ug/0.5 ul / hemisphere into the CeA immeadiately after 10min access to 0.125% saccharin and 15 min before LiCl injection (12 ml/kg, 0.15 M, i.p.) Inject 0.5 ul over 1 minute; leave injector in place for 1 min after injection to prevent backflow along the injection tract.